MysteryVibe, a sextech brand founded on the principle that pleasure should be universally accessible, has been at the forefront of designing vibrators aimed at not only enhancing pleasure but also treating symptoms of sexual dysfunction in both women and men.
Last month MysteryVibe’s Crescendo 2 vibrator was the focal point of a new study published in the Journal of Sexual Medicine. The research found that when used before intercourse and combined with cognitive behavior therapy (CBT), Crescendo 2 is an effective remedy for Female Sexual Arousal Disorder (FSAD). This discovery adds to a growing body of evidence indicating that MysteryVibe’s devices offer successful treatments for various sexual arousal challenges, such as GPPPD and vaginal atrophy. Importantly, all products by MysteryVibe, including Crescendo 2, are FDA-registered medical devices and qualify for FSA/HSA eligibility.
FSAD is typified by issues related to sexual desire, orgasm, and sometimes pain. Often, these symptoms arise due to hormonal shifts that might be triggered by life events such as pregnancy, perimenopause, or menopause. At present, women grappling with FSAD due to menopause find themselves with restricted options to alleviate their symptoms. While hormone therapy is an option, it can be financially taxing and might not be suitable for everyone.
Comparatively, men and individuals with penises have more readily accessible remedies, such as Viagra, Cialis, and their generic variants, to support their sexual lives during the aging process. This ongoing disparity emphasizes the importance of brands like MysteryVibe, who are committed to creating innovative solutions for the myriad challenges faced by women as they age.
